Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. Frontiers in Pharmacology, 2019, 9, 1521. doi : 10.3389/fphar.2018.01521, PMID : 30687090 Objective: Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. In this study we aimed to report the experience of parents who administer, under supervision, oral [...]
Lire la suiteWhat Is the CBD Dosing Required for Effective Pain Relief ? Damian McNamara, CME, Laurie Barclay, MD Posted: 12/14/2018 Clinical Context The effects of cannabis in humans include euphoria, increased sensitivity to external experience, relaxation, and potential for addiction. Cannabidiol is a compound in the cannabis plant that lacks euphoric and addictive qualities and that may be useful to treat conditions including chronic pain, nausea, epilepsy, psychosis, and anxiety. The optimal therapeutic dose of CBD has not yet been determined, and it has been used in a wide dose range from 2.85 to 50 mg/kg/day. The therapeutic effects of CBD appear to emanate from its interaction [...]
Lire la suiteCannabis and Mood Disorders Aliya M. Lucatch, Alexandria S. Coles, Kevin P. Hill & Tony P. George Current Addiction Reports, 2018 Sep, 5, 3, 336-345. doi: 10.1007/s40429-018-0214-y. Epub 2018 May 10. # Springer International Publishing AG, part of Springer Nature 2018 Abstract : Purpose of Review : The present review will provide an overview of the neurobiology, epidemiology, clinical impact, and treatment of cannabis use disorder (CUD) in mood disorders. Recent Findings : Patients with mood disorders including major depressive disorder (MDD) and bipolar disorder (BD) have higher rates of cannabis use, and CUD compared to the general population. Reasons for this association are not clear, nor [...]
Lire la suiteA Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain Griffin A. TYREE, Reith SARKAR, Brandon K. BELLOWS, Ronald J. ELLIS, Joseph HAMPTON ATKINSON, Thomas D. MARCOTTE, Mark S. WALLACE, Igor GRANT, Yuyan SHI, James D. MURPHY, and David J. GRELOTTI Cannabis and Cannabinoid Research, Volume 0, Number 0, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0027 Abstract Background : A recent meta-analysis affirmed the benefit of medicinal cannabis for chronic neuropathic pain, a disabling and difficult-to-treat condition. As medicinal cannabis use is becoming increasingly prevalent among Americans, an exploration of its economic feasibility is warranted. We present this cost-effectiveness analysis of adjunctive [...]
Lire la suiteMedical cannabis : An oxymoron ? Physicians’ perceptions of medical cannabis Yuval ZOLOTOVA, Simon VULFSONS, Dana ZARHIN, Sharon SZNITMAN International Journal of Drug Policy, 2018, 57, 4-10. A B S T R A C T : Background : Medical cannabis policies are changing in many places around the world, and physicians play a major role in the implementation of these policies. The aim of this study was to gain a deeper understanding of physicians’ views on medical cannabis and its possible integration into their clinic, as well as to identify potential underlying factors that influence these perceptions. Methods : Qualitative narrative analysis of in-depth interviews [...]
Lire la suiteThe Role of CB2 Receptor in the Recovery of Mice after Traumatic Brain Injury Lital MAJID, Sami HEYMAN, Merav ELGALI ... Esther SHOHAMI et al. Journal of Neurotrauma, Nov 2018, 36, 1-11 DOI: 10.1089/neu.2018.6063 Abstract : Cannabis is one of the most widely used plant drugs in the world today. In spite of the large number of scientific reports on medical marijuana, there still exists much controversy surrounding its use and the potential for abuse due to the undesirable psychotropic effects. However, recent developments in medicinal chemistry of novel non-psychoactive synthetic cannabinoids have indicated that it is possible to separate some of the therapeutic effects [...]
Lire la suiteIs cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms ? José Alexandre S. CRIPPA,· Jaime E. C. HALLAK, · Antônio W. ZUARDI · Francisco S. GUIMARAES, · Vitor TUMAS, · Rafael G. dos SANTOS European Archives of Psychiatry and Clinical Neuroscience, 2019, 269(1) DOI : 10.1007/s00406-019-00982-6 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is [...]
Lire la suiteCannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report Amanda REIMAN, Mark WELTY, Perry SOLOMON Cannabis and Cannabinoid Research, 2017, Vol 2, n°1 Abstract Introduction: Prescription drug overdoses are the leading cause of accidental death in the United States. Alternatives to opioids for the treatment of pain are necessary to address this issue. Cannabis can be an effective treatment for pain, greatly reduces the chance of dependence, and eliminates the risk of fatal overdose compared to opioid-based medications. Medical cannabis patients report that cannabis is just as effective, if not more, than opioid-based medications for pain. Materials and Methods: The current study examined the [...]
Lire la suiteAn Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Kerstin IFFLAND, Franjo GROTENHERMEN Cannabis and Cannabinoid Research, 2017, 2, (1), 139–154. DOI: 10.1089/can.2016.0034 https://www.liebertpub.com/doi/10.1089/can.2016.0034?utm_source=sfmc&utm_medium=email&utm_campaign=CAN%20OA%20Feb%201%202019&d=2/1/2019&mcid=1909944349 Abstract Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy [...]
Lire la suiteMedicinal cannabis : History, Pharmacology and Implication for the Acute Care Settings Mary Barna Bridgeman, PharmD, BCPS, BCGP; and Daniel T. Abazia, PharmD, BCPS, CPE Pharmacy & Therapeutics®, 2017 • Vol. 42 No. 3, pp 180-188. INTRODUCTION Medicinal cannabis, or medicinal marijuana, is a therapy that has garnered much national attention in recent years. Controversies surrounding legal, ethical, and societal implications associated with use; safe administration, packaging, and dispensing; adverse health consequences and deaths attributed to marijuana intoxication; and therapeutic indications based on limited clinical data represent some of the complexities associated with this treatment. Marijuana is currently recognized by the U.S. Drug Enforcement Agency’s [...]
Lire la suite